Early day motion 1274

MS WEEK

Main content

Total number of signatures: 90

Abbott, Diane Ainsworth, Bob Anderson, David Betts, Clive
Blackman, Bob Blomfield, Paul Blunkett, David Bottomley, Peter
Brady, Graham Brooke, Annette Burstow, Paul Campbell, Gregory
Campbell, Ronnie Caton, Martin Clark, Katy Connarty, Michael
Cooper, Rosie Crausby, David Crockart, Mike Cunningham, Jim
Cunningham, Tony Davies, Philip Dobbin, Jim Dodds, Nigel
Dorries, Nadine Dowd, Jim Durkan, Mark Ellman, Louise
Engel, Natascha Farron, Tim George, Andrew Gilbert, Stephen
Glass, Pat Glindon, Mary Godsiff, Roger Gray, James
Hamilton, Fabian Hancock, Mike Hemming, John Hepburn, Stephen
Hermon, Lady Hoey, Kate Hopkins, Kelvin Jackson, Glenda
Kaufman, Gerald Lavery, Ian Leech, John Lewis, Julian
Lloyd, Stephen Llwyd, Elfyn Long, Naomi Love, Andrew
Lucas, Caroline Marsden, Gordon McCrea, Dr William McDonnell, Alasdair
McDonnell, John Meacher, Michael Meale, Alan Mearns, Ian
Mitchell, Austin Morrice, Graeme Morris, Grahame M Mulholland, Greg
O'Donnell, Fiona Osborne, Sandra Reevell, Simon Riordan, Linda
Ritchie, Margaret Rotheram, Steve Roy, Lindsay Ruane, Chris
Ruddock, Joan Sanders, Adrian Shannon, Jim Sharma, Virendra
Simpson, David Skinner, Dennis Streeter, Gary Sutcliffe, Gerry
Tami, Mark Thornton, Mike Walley, Joan Ward, David
Watts, Dave Weir, Mike Williams, Mark Williams, Roger
Wilson, Sammy Wright, David

That this House welcomes MS Week 2014, which takes place from 28 April to 4 May; understands that there are over 100,000 people living with multiple sclerosis (MS) in the UK and that over the last decade the availability of treatments for MS has been instrumental in supporting many people to manage their condition and its symptoms; supports the notion that everyone with MS should be able to access the right treatment at the right time; notes recent research by the MS Society that highlights current barriers to accessing disease modifying treatments and considers that, with three new treatments just authorised by the European Commission, this situation needs to be urgently addressed; further welcomes the MS Society's Treat Me Right campaign, which aims to ensure that licensed treatments for MS are freely available to everyone who needs them and that people with MS are active, informed and equal partners in their care; and further supports the need for fresh thinking on what steps must be taken in England to achieve this goal with the partnership of the Government, the NHS, the National Institute for Health and Care Excellence, the voluntary sector, industry and people affected by MS.